TrialDiabetes care2021

Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial.

Yvo J M Op den Kamp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.